UCB Reports Results of Bimekizumab in P-III BE VIVID Study to Treat Moderate to Severe Chronic Plaque Psoriasis

UCB’s Nayzilam (midazolam) Receives FDA’s Approval for the Treatment of Seizure Cluster in Epilepsy in the US


  • The P-III BE VIVID study involves assessing of Bimekizumab vs PBO & Ustekinumab in 570 patients with chronic plaque psoriasis for at least 6mos. prior to screening and with an affected body surface area of at least 10% and PASI of at least 12
  • The P-III BE VIVID study results: @16wks. met its co-1EPs of at least 90% improvement in PASI 90 and IGA score of clear or almost clear (IGA 0/1) and is superior to ustekinumab in achieving PASI 90 and IGA 0/1 and superior to PBO in achieving PASI 100 or IGA 0
  • Bimekizumab is an investigational mAb, selectively neutralizing IL-17A and IL-17F with its safety & efficacy being evaluated in PsA, AS and nr-axSpA

Click here to­ read full press release/ article | Ref: UCB | Image: UCB